title: Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes.
abstract: OBJECTIVE
  The study was aimed to investigate the effect of voglibose or acarbose as an add-on treatment in overweight/obese type 2 diabetes (T2DM) patients who are uncontrolled with metformin and sulfonylureas (SUs) in Western part of India.
  
  
  METHODS
  A retrospective study included 77 participants (BMI≥25kg/m(2); HbA1c level>8% and<9.5%) with overweight/obese T2DM. These participants were treated with either voglibose or acarbose. Glycemic parameters (fasting blood glucose and glycated hemoglobin [HbA1c]), bodyweight, BMI and lipid parameters were evaluated at baseline, 3-month, 6-month and 9-month of treatment. Adverse events were also captured at respective time points.
  
  
  RESULTS
  Voglibose showed significant reduction in HbA1c and bodyweight with short duration of treatment (6 months; P<0.05 and 9 months; P<0.01) whereas acarbose showed significant reduction with longer duration of treatment (9 months; P<0.05) when compared with baseline. Moreover, both treatment groups were reported with reduction in BMI. Further, significant improvement in lipid parameters except LDL and HDL were observed in both treatment groups when compared with baseline. None of participant was discontinued due to side effects of the treatment. In addition, the frequency of hypoglycemia was decreased in both treatment groups.
  
  
  CONCLUSIONS
  Voglibose or acarbose as an add-on treatment with metformin and sulfonylureas in uncontrolled obese/overweight T2DM provides desired glycemic control, reduces bodyweight and improves lipid parameters with good tolerability profile.
authors.affiliation: Department of Research, DiaCare - An Advance Diabetes Care Centre, Ahmedabad, India; Faculty of Pharmaceutical sciences, Pacific University, Udaipur, India. Electronic address: talaviyapraful@gmail.com.
authors.forename: Praful A
authors.initials: PA
authors.lastname: Talaviya
authors.affiliation: Department of Research, DiaCare - An Advance Diabetes Care Centre, Ahmedabad, India.
authors.forename: Banshi D
authors.initials: BD
authors.lastname: Saboo
authors.affiliation: Department of Pharmacology, L.M. College of Pharmacy, Ahmedabad, India.
authors.forename: Hardik G
authors.initials: HG
authors.lastname: Dodiya
authors.affiliation: C. T. Institute of Pharmaceutical Sciences, Jalandhar, India.
authors.forename: Shaival K
authors.initials: SK
authors.lastname: Rao
authors.affiliation: Joshi Clinics, Mumbai, India.
authors.forename: Shashank R
authors.initials: SR
authors.lastname: Joshi
authors.affiliation: Department of Pharmacology, Institute of Pharmacy - Nirma University, Ahmedabad, India.
authors.forename: Vipul B
authors.initials: VB
authors.lastname: Modh
authors.affiliation: Lecturer, Rai University, Ahmedabad, India.
authors.forename: Sneha V
authors.initials: SV
authors.lastname: Ghadiya
mesh_terms: D020909:Acarbose / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D001786:Blood Glucose; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D065089:Glycoside Hydrolase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007194:India; D007294:Inositol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008055:Lipids / Q000097:blood; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D009765:Obesity / Q000150:complications*; D012189:Retrospective Studies; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D020909:Acarbose; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007294:Inositol; D008055:Lipids; D008687:Metformin; D013453:Sulfonylurea Compounds; C517652:hemoglobin A1c protein, human; C102817:voglibose
keywords: Hb1Ac; Hypoglycemia; Obese/overweight T2DM; Sulfonylureas